SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Szukaj
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Our Innovation Strategy
Our discovery research strategy is designed to sustain our track record of innovation and look for new and breakthrough medicines.
Retinal Health Research
Read about our holistic approach to retinal health research.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
A Clear Vision
Take a tour of our journey into Retinal Health through this interactive infographic or descriptive audio recording, and learn how we aim to preserve or restore vision in people with retinal diseases.
Collaboration Driving Innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Contact Us
Contact our partnering team to discuss your project and learn more about how we can work together.
About Boehringer Ingelheim Partnering Days
Find out more about our partnering days and how we can work together to accelerate your science
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Retinal health
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in Retinal Health.
Historia Boehringer Ingelheim w latach 1948-1990,
Historia Boehringer Ingelheim w latach 1948-1990, z kamieniami milowymi
Historia (1885-1948): Nowatorskie początki
Historia Boehringer Ingelheim od rozpoczęcia działalności w 1885 roku do 1948 roku, z kamieniami milowymi i ważnymi produktami
1990-2022: Wartość dzięki innowacjom
The Boehringer Ingelheim history from 1990 to 2022, with milestones
Championing novel science
Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Advancing regenerative medicine
Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, dzieli się swoimi spostrzeżeniami dotyczącymi zarządzania aliansami i jego wkładem w rozwój udanych i długotrwałych partnerstw.